JAVELIN Bladder 100: Phase III Trial of Maintenance Avelumab After First-line Platinum Chemotherapy in Advanced Urothelial Carcinoma

May 29-31, 2020; Online at meetings.asco.org/am
Maintenance avelumab plus BSC significantly prolonged OS in the overall population and in patients with PD-L1–positive disease.
Format: Microsoft PowerPoint (.ppt)
File Size: 247 KB
Released: June 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer and EMD Serono, Inc.

Related Content

Downloadable slides on current treatment landscape of patients with ovarian cancer from Clinical Care Options (CCO)

Bradley J. Monk, MD, FACS, FACOG Released: December 3, 2020

From Clinical Care Options (CCO), a short video with Kinjal Patel, PharmD, BCOP on use of erdafitinib for patients with advanced or metastatic urothelial carcinoma

person default Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Short video from CCO: Nursing considerations with new therapies for advanced urothelial carcinoma, featuring Susan Roethke, CRNP, MSN, AOCNP, ANP-BC

Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 30, 2020 Expired: November 29, 2021

From Clinical Care Options (CCO), watch a short video with Kinjal Patel, PharmD, BCOP, reviewing new treatment options for patients with advanced or metastatic urothelial carcinoma

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 13, 2020 Expired: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue